TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06028672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: 200mg q2w intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actinomycin-D
Description: 1.25mg/m2，2mg max dose, q2w, intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Actinomycin-D
Description: 1.25mg/m2，2mg max dose, q2w, intravenous
Study: NCT06052189

Intervention type: PROCEDURE
Intervention: Ultrasound
Description: Ultrasonographic parameters: in the parasagittal plane (1cm from midline) with the patient lying supine, without a pillow, head, and neck in the neutral position, looking straight ahead with mouth closed and the tongue on the floor of the mouth without any movement.

Intervention type: PROCEDURE
Intervention: Ultrasound
Description: Ultrasonographic parameters: in the parasagittal plane (1cm from midline) with the patient lying supine, without a pillow, head, and neck in the neutral position, looking straight ahead with mouth closed and the tongue on the floor of the mouth without any movement.
Study: NCT04742972

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: SABR is delivered to all sites of oligometastasis with continuation of Enzalutamide. Further oligo-progressive lesions may be treated with SABR if possible. Upon progression at sites not amenable to SABR, the patient may receive any of the options in SOC Arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SOC
Description: Three options:~1. Continuation of Enzalutamide~2. Observation~3. Switch to next line treatment
Study: NCT05395039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VCHIPS
Description: Participants in this group will have the opportunity to receive virtual visits with the patient during the hospital stay, led by a study nurse.
Study: NCT06266936

Intervention type: OTHER
Intervention: No intervention
Description: The study involves longitudinal monitoring of the state of health of the specific population of students in care courses, from their entry into university studies (first year) until their final year of study, i.e. from 5 to 13 years depending on the course and the different universities.
Study: NCT06283225

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pia-App
Description: The dysmenorrhoea app (Pia-App) is evidence-based and helps patients to implement continuous multimodal (pain) treatment that is integrated into everyday life. Symptoms, events, influencing factors and examinations can be recorded in a specialised diary. Diary evaluations and learning modules on dysmenorrhoea and other relevant topics promote understanding of the condition and self-efficacy. An intelligent evaluation suggests suitable evidence-based and appropriate exercises. In the learning modules, patients can learn about the menstrual cycle, menstrual pain and self-management methods in a structured way. For example, there are structured courses on physiotherapy, yoga, stress reduction and relaxation methods such as progressive muscle relaxation and autogenic training.
Study: NCT06521424

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AG1 - Nutritional Supplement
Description: A foundational nutritional supplement consisting of vitamins, minerals, probiotics, prebiotics, and whole food ingredients

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin placebo
Study: NCT05343715

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Agalsidase beta from Biosidus 1 mg/kg
Description: Patients received an infusion of 1 mg/kg of Agalsidase Beta from Biosidus. Final infusion dose is achieved with lyophilized drug at concentration 35 mg and 5 mg
Study: NCT05678933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine (1.4mg/ m2，Max dose 2mg) will be administered by an intravenous injection on day 1of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone (100 mg) will be taken orally from day 1-5 of each 21-day cycle.
Study: NCT05048199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pressure regulated volume-controlled mode of ventilation
Description: Cardiac output non-invasive monitor for measuring SV. Hemodynamic variables including heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP), stroke volume (SV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), and systolic time ratio (STR), Arterial oxygen saturation (Sao2), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be recorded.~These variables will be obtained before induction of anaesthesia (T1) skin incision (T2), then every 30 min till the resection of the urinary bladder (T3a, T3b, T3c, .... etc). The mode of ventilation will swift to the other mode 5 minutes after cystectomy (T4), then every 30 min till end of the urinary diversion (T5a, T5b, T5c, .... etc), end of surgery (T6), and postoperative every 4h for 24 hours( P1-P6).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: volume-controlled mode of ventilation
Description: Cardiac output non-invasive monitor will be used for measuring SV. Hemodynamic variables including heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP), stroke volume (SV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), and systolic time ratio (STR), Arterial oxygen saturation (Sao2), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be recorded.~These variables will be obtained before induction of anaesthesia (T1) skin incision (T2), then every 30 min till the resection of the urinary bladder (T3a, T3b, T3c, .... etc). The mode of ventilation will swift to the other mode 5 minutes after cystectomy (T4), then every 30 min till end of the urinary diversion (T5a, T5b, T5c, .... etc), end of surgery (T6), and postoperative every 4 hours for 24 hours (P1-P6).
Study: NCT04854577

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Opioid Free Anesthesia
Description: Patients will be administered a combination of a pre-incisional pecto-intercostal fascial plane block and a standardized opioid free anesthetic regimen consisting of dexmedetomidine, esketamine and lidocaine.
Study: NCT05865262

Intervention type: DIAGNOSTIC_TEST
Intervention: ECG
Description: A triplicate ECG and a blood test will be done during a medical consultation as part of the usual endocrinology follow-up. Included individuals seen prior to initiation of GAHT, will be assessed a second time (at least one month after GAHT start) with a triplicate ECG and a blood test similar to inclusion visit. Included individuals already on GAHT will be seen only once at the inclusion visit.~Triplicates of 10seconds 12-lead digitized electrocardiogram will be recorded after few minutes of rest in the supine position. Electrocardiograms will be acquired with Mindray ECG BeneHeart R12. For each subject, RR, PR, QRS and QT interval durations will be assessed with a semiautomatic approach using the median representative beats (overlap method) generated from 10seconds ECG with a good quality (CalECG v3.7; AMPS, LLC). The QT interval will be measured and corrected for heart rate by Fridericia's formula.

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test (assessing ionic and hormonal circulating levels)
Description: Blood samples for the determination of serum concentrations of estradiol, progesterone, testosterone, FSH, and LH will be collected on the same day as the ECG, in a dry tube and further assayed in the immunology laboratory of Bordeaux University Hospital (France). Estradiol, progesterone, FSH, and LH plasma concentrations will be assayed by immunochemiluminescence (Architect i2000SR; Roche Diagnostics), and testosterone levels by liquid chromatography mass spectrometry. Kalemia and calcemia will be collected in a BD Vacutainer tube with heparin lithium and separator, further assayed at the biochemistry laboratory of Bordeaux University Hospital by indirect potentiometric measurement (Architect c16000) and Arsenazo III SRM 956 colorimetrie (Architect c16000).
Study: NCT04854577

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Anesthetic Regimen
Description: Patients will be administered a traditional anesthetic regimen which is based on sufentanil dosage. The dosage is at the discretion of the attending anesthesiologist.
Study: NCT05225480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Illness perception conversation
Description: A conversation based on the indvidual's knee pain related illness perceptions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: research motivation conversation
Description: A conversation based on the indvidual's motivation for participating in research
Study: NCT05214495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical oral Omega-3 hydrogel
Description: Topical oral Omega-3 hydrogel prepared from fish oil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional preventive treatment
Description: topical treatment including antifungal agents, anti-inflammatory mouthwash, sodium bicarbonate mouthwash.~Topical anesthetics agent, topical analgesic gel as well as systemic analgesics (if needed)
Study: NCT05560477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM3101
Description: Injectable drug product.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: 2 mL 0.9% normal saline
Study: NCT04847011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Patients undergo a 5-10 day fasting period with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Patients undergo a 5-10 day fasting period with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al.
Study: NCT06558552

Intervention type: OTHER
Group type: OTHER
Intervention: transcutaneous pulsed radiofrequency
Description: Instead of invasive application of PRF directly to the lesion area or nerve, transcutaneous pulsed radiofrequency (TCPRF) is applied noninvasively.

Intervention type: OTHER
Group type: OTHER
Intervention: extracorporeal shock wave therapy (ESWT)'
Description: A shock wave is created together with sound and pressure waves. Changes at the cellular level with the shock wave include increased collagen production, increased blood flow in the applied area, acceleration of wound healing and cellular proliferation.
Study: NCT05061732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 20mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 20mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 20mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 20mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 20mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 20mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 20mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 20mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 20mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole
Description: 20mg bid
Study: NCT05359315

Intervention type: DRUG
Intervention: Interferon-Gamma
Description: received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein
Study: NCT05061732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate
Description: 0.6g bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate
Description: 0.6g bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate
Description: 0.6g bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate
Description: 0.6g bid
Study: NCT06123715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Drug: Patients in the intervention group will receive 2g Vitamin C orally within 4 hours of the start of the surgery followed by 500 mg of Vitamin C to be taken orally twice a day from post-op day1 to day 56.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Patients in the placebo group will receive identical placebo capsules taken orally within 4 hours of the start of the surgery followed by placebo capsules taken orally twice a day from post-op day 1 to day 56.
Study: NCT05607602

Intervention type: OTHER
Intervention: Comparison of blood samples between the two groups
Description: In this study we will perform global haemostatic assays such as activated partial thromboplastic time (APTT), and prothrombin time (PT). However, these tests provide information about the haemostatic process until the point of initial fibrin formation and ignore the procedure of thrombin generation\[18\]. In this study we will perform Thrombin Generation studies, Plasma clot Lysis, and RNA sequencing in addition to standard laboratory tests (APTT, PT, FVIII:C, fibrinogen (using Clauss methods), platelet count, liver and renal function tests.

Intervention type: OTHER
Intervention: Comparison of blood samples between the two groups
Description: In this study we will perform global haemostatic assays such as activated partial thromboplastic time (APTT), and prothrombin time (PT). However, these tests provide information about the haemostatic process until the point of initial fibrin formation and ignore the procedure of thrombin generation\[18\]. In this study we will perform Thrombin Generation studies, Plasma clot Lysis, and RNA sequencing in addition to standard laboratory tests (APTT, PT, FVIII:C, fibrinogen (using Clauss methods), platelet count, liver and renal function tests.
Study: NCT05165732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental vaccine 1
Description: Inactivated COVID-19 vaccine manufactured by Sinovac Life Sciences Co., Ltd.600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental vaccine 1
Description: Inactivated COVID-19 vaccine manufactured by Sinovac Life Sciences Co., Ltd.600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental vaccine 1
Description: Inactivated COVID-19 vaccine manufactured by Sinovac Life Sciences Co., Ltd.600SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental vaccine 2
Description: Inactivated COVID-19 vaccine manufactured by Beijing Institute of Biological Products Co.,Ltd.4ug inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental vaccine 3
Description: Inactivated COVID-19 vaccine manufactured by Wuhan Institute of Biological Products Co.,Ltd.200WU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.
Study: NCT05061732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate
Description: 0.6g bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate
Description: 0.6g bid
Study: NCT05343715

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fabrazyme (agalsidase beta) 1 mg/kg
Description: Patients received an infusion of 1 mg/kg of Fabrazyme. Final infusion dose is achieved with lyophilized drug at concentration 35 mg and 5 mg
Study: NCT06497751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple-based Dyadic Coping Group
Description: Session one: We-disease appraisal (30 minutes). Couples will work toward a congruent perception of HIV as a shared disease, enhancing illness control.~Session two: Couple communication (30 minutes). Couples will learn basic knowledge of effective communication and undertake skill-building exercises focusing on effective communication techniques.~Session three: Dyadic coping (60 minutes). Couples will learn basic knowledge of dyadic coping and work on skill-building exercises (e.g., three-phase dyadic coping exercise) to enhance support mobilization.
Study: NCT05432830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid Flavor 1
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with sweet e-cigarette flavor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid Flavor 1
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with sweet e-cigarette flavor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid Flavor 1
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with sweet e-cigarette flavor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid Flavor 2
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with cooling e-cigarette flavor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid Flavor 2
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with cooling e-cigarette flavor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid Flavor 2
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with cooling e-cigarette flavor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid Flavor 3
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with unflavored e-cigarette flavor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid Flavor 3
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with unflavored e-cigarette flavor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-liquid Flavor 3
Description: E-liquid containing 36mg/ml pronated nicotine will be administered with unflavored e-cigarette flavor.
Study: NCT05061732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate
Description: 0.6g bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth potassium citrate
Description: 0.6g bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 0.4g qid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 0.4g qid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 0.4g qid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 0.4g qid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 0.5g bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 0.5g bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: 0.5g qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: 0.5g qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: 1g tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: 1g tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: 1g tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: 1g tid
Study: NCT05070455

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Asceniv™
Description: Each subject will receive an intravenous infusion of Asceniv™ on Study Day 1 (required to be within 28 days of screening) and every 21 or 28 days thereafter according to their current interval of IGIV treatment. Subjects will receive Asceniv™ at the same dose or higher dose if medically appropriate (300-800 mg/kg), every 21 or 28 days for five months (seven or six doses respectively).
Study: NCT05483023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluorofuranylnorprogesterone PET / MRI
Description: Subjects will receive a PET/MRI with 18F-fluorofuranylnorprogesterone tracer
Study: NCT05061732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: 1g tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 0.4g tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 0.4g tid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 0.4g tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 0.1g bid
Study: NCT05716867

Intervention type: BIOLOGICAL
Intervention: Measurement of salivary cystatin S protein levels in saliva
Description: The human cystatin S enzyme-linked immunosorbent assay (ELISA) kit will be used to measure the amounts of cystatin S in saliva for cases and controls

Intervention type: BIOLOGICAL
Intervention: Measurement of salivary cystatin S protein levels in saliva
Description: The human cystatin S enzyme-linked immunosorbent assay (ELISA) kit will be used to measure the amounts of cystatin S in saliva for cases and controls
Study: NCT05744856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-care with informal support
Description: The detailed content of the self-care with informal support intervention will be developed at participatory co-creation workshops involving pregnant women with GDM, their informal support persons, and health care staff.~It is expected that intervention will include educational pamphlets regarding GDM and digital GDM education through videos and text messages. Further, digital coaching will be conducted and networking among intervention participants via the Vietnamese messaging app Zalo. In addition, each woman will be invited to include one informal support person in the intervention activities.~GDM education will concern coaching on diet and exercise during pregnancy and after delivery and coaching on breastfeeding and infant/child nutrition.
Study: NCT05070793

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Culturally adapted interpersonal psychotherapy
Description: Individual psychotherapy based on Brief Interpersonal Psychotherapy, culturally adapted for transgender and nonbinary individuals.